EU AI Act Could ‘Set Back’ Benefits Of AI In Drug Development If Applied To R&D

 
• By Eliza Slawther
  
There is concern among some industry stakeholders that the EU AI Act could extend further than necessary (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from AI

More from Advanced Technologies